PEMF for Hip Bursitis
& Lateral Hip Pain.

June 2026 · 9 min read · Clinical Protocol

Greater Trochanteric Pain Syndrome: A Frequently Misdiagnosed Condition

Hip bursitis — formally termed Greater Trochanteric Pain Syndrome (GTPS) — encompasses a spectrum of lateral hip pathologies including trochanteric bursitis, gluteus medius tendinopathy, and gluteus minimus tendinopathy. The traditional "hip bursitis" diagnosis historically attributed all lateral hip pain to bursal inflammation; modern imaging evidence shows that isolated bursitis without concurrent gluteal tendinopathy accounts for fewer than 20% of GTPS cases. The majority involve tendon pathology as the primary driver, with bursal irritation secondary to altered loading mechanics.

GTPS affects an estimated 10–25% of adults presenting with hip pain in primary care and sports medicine settings. In the Philippines, the combination of high-prevalence risk factors — female sex (GTPS is 3–4× more common in women), middle age (peak onset 40–60 years), sedentary lifestyle, and high BMI — creates a large, underserved patient population for PEMF-equipped clinics.

Anatomy of Greater Trochanteric Pain Syndrome

Three structures converge at the greater trochanter in a complex that is vulnerable to compressive and tensile overload:

• Gluteus medius tendon — inserts on the superolateral facet of the greater trochanter; primary hip abductor and pelvic stabilizer during single-leg stance. Tendinopathy develops in the insertional zone under compressive load (particularly with cross-body adduction and internal rotation — e.g., sitting with legs crossed).
• Gluteus minimus tendon — inserts on the anterolateral facet; assists hip abduction and internal rotation. Less commonly injured in isolation; often co-pathological with gluteus medius tendinopathy.
• Trochanteric bursae (2–3 bursae) — lie between the greater trochanter and the IT band/gluteal tendons; reduce friction during hip motion. Secondary bursitis develops when primary tendinopathy alters load distribution; rare as the sole pathology.

The 2020–2025 literature has increasingly reclassified GTPS from a "bursitis" to a "tendinopathy" condition, with clinical implications for both diagnosis and treatment. PEMF is particularly well-suited to this updated pathophysiology, as its mechanisms target both the tendinopathic tissue repair process and the peritendinous inflammatory environment.

Who Gets Greater Trochanteric Pain Syndrome?

Clinical Presentation and Diagnosis

GTPS has a characteristic clinical fingerprint that allows confident clinical diagnosis without imaging in most cases:

• Location: lateral hip, centered on or just posterior to the greater trochanter. May radiate down the lateral thigh (not below the knee — this distinguishes it from hip OA referred pain and lumbar radiculopathy)
• Aggravating positions: lying on the affected side (classic "can't sleep on my side" complaint), cross-leg sitting, climbing stairs, prolonged standing on one leg
• Relieving positions: lying supine with a pillow between the knees, avoiding hip adduction
• Palpation: point tenderness directly over the greater trochanter, often exquisitely sensitive
• FABER test (Patrick's test): pain reproduced with hip flexion, abduction, and external rotation — positive in 80–90% of GTPS
• Single-leg stance test (Trendelenburg): contralateral pelvis drops in 60–75% of GTPS cases, confirming gluteus medius insufficiency

Why Conventional Treatments Fail — And What PEMF Adds

GTPS has historically been managed with corticosteroid injections, physiotherapy, and rest — an approach with documented high recurrence rates:

• Corticosteroid injection: provides 4–6 weeks of pain relief in 60–80% of cases but shows 73% recurrence by 12 months. Repeated injections weaken the gluteal tendon collagen matrix, increasing rupture risk — a particular concern in already-degenerated tendinopathic tissue
• Physiotherapy alone: hip abductor strengthening is effective (12-week outcomes comparable to injection), but requires 12–16 weeks of supervised exercise compliance that many patients fail to maintain
• Rest: reduces acute inflammation but does not address the tendinopathic tissue biology; pain returns with activity resumption in 60–70% of resting-only cases
• NSAIDs: manage acute flare but have no effect on underlying tendon degeneration and carry GI/renal risk with extended use

PEMF addresses the biological gap in all of these approaches — active, directed tendon repair — while complementing rather than replacing the biomechanical correction that physiotherapy provides.

How PEMF Treats Greater Trochanteric Pain Syndrome: Four Mechanisms

1. Tendon anti-inflammation: PEMF suppresses peritendinous TNF-α and IL-1β through adenosine-A2A receptor activation, reducing the pro-inflammatory cytokine burden that perpetuates gluteal tendinopathy. This is the same mechanism confirmed in periarticular joint conditions (PMC9110240, 11 RCTs, n=614) and directly applicable to gluteal tendon insertion inflammation.
2. Collagen synthesis and alignment: low-frequency PEMF (10–25 Hz) stimulates gluteal tendon fibroblasts to upregulate Type I collagen production and organize fiber deposition along tensile load lines (PMC7093940). This converts reactive tendinopathy — the reversible early phase — toward a repaired tissue state rather than degenerative tendinopathy.
3. Muscle tone normalization: a controlled RCT (PMC12467020, n=30) demonstrated that PEMF significantly outperformed therapeutic massage in reducing hypertonic muscle tone in the gluteal and lateral thigh musculature (p=0.015, η²=0.28 large effect, sustained at follow-up). Normalizing TFL and IT band tension directly reduces compressive load on the trochanteric bursa and gluteal insertions.
4. Microcirculation and bursa resolution: PEMF-induced nitric oxide release increases peritrochanteric capillary perfusion by 28–34%, accelerating resorption of bursal fluid accumulation and improving nutrient delivery to the avascular zones of the gluteal tendon insertion.

PEMF Protocol for Greater Trochanteric Pain Syndrome

Session frequency: Acute phase: 3–4×/week. Repair phase: 2–3×/week. Consolidation: 2×/week. Maintenance: 1–2×/month. Minimum course for acute GTPS: 8–10 sessions. Full protocol for chronic/recurrent GTPS: 16–24 sessions over 8–10 weeks.

PEMF vs. Conventional GTPS Treatments

Combining PEMF with the GTPS Rehabilitation Continuum

The highest-outcome GTPS protocol integrates PEMF with load management and progressive tendon rehabilitation:

• Load management (concurrent from Week 1): eliminate compressive positions — no cross-leg sitting, sleeping on the unaffected side with pillow support, avoiding deep squat positions. PEMF accelerates recovery within these modified-load parameters.
• Isometric gluteal loading (Week 2): gluteus medius isometrics can begin earlier than standard protocols (typically Week 3–4) because PEMF has reduced acute bursal/tendon inflammation, making load application tolerable. Isometrics provide pain-inhibition and early tendon stress-shielding.
• Progressive isotonic loading (Week 4–6): single-leg bridge, side-lying hip abduction, clamshells — begin when PEMF has transitioned the tissue from reactive tendinopathy to remodeling phase. PEMF post-exercise sessions drive collagen alignment concurrent with loading stimulus.
• Return-to-walking/activity (Week 6–10): graduated stair climbing and walking distances with PEMF consolidation sessions 2×/week to sustain collagen remodeling momentum.

Co-occurring Conditions: Addressing the Full Clinical Picture

GTPS rarely presents in isolation. Philippine clinic operators should screen for — and PEMF can address — common co-pathologies:

• Lumbar spine dysfunction (60–70% co-occurrence): PEMF lumbar add-on sessions normalize gluteal inhibition from L4/L5/S1 root involvement, which is often the primary driver of gluteus medius weakness perpetuating the trochanteric overload cycle
• Hip osteoarthritis (20–30% co-occurrence): PEMF anti-inflammatory protocols for OA (PMC9110240 meta-analysis, pain SMD=0.71 p=0.03, stiffness SMD=1.34 p=0.003) concurrently address both the articular and periarticular pathology
• Knee OA or medial compartment pain (25–35% co-occurrence): altered hip biomechanics from GTPS redistribute load to the knee — addressing both simultaneously improves outcomes and reduces total session count
• Sacroiliac joint dysfunction: SI joint pain and GTPS share biomechanical drivers (pelvic instability, hip abductor weakness); combined lumbar-pelvic PEMF protocols are efficient and clinically effective

Philippine Market Context: The Underserved Hip Pain Patient

GTPS represents a compelling PEMF clinic segment in the Philippines for three reasons:

• Volume: hip pain is the third most common musculoskeletal complaint in the Philippines after back pain and knee pain. With GTPS accounting for a significant proportion of lateral hip pain presentations, and a target demographic of women aged 40–60 (a large and growing cohort), patient volume is reliable
• Treatment dissatisfaction: Filipino GTPS patients are frequently managed with repeated corticosteroid injections and NSAIDs — both high-recurrence strategies. When presented with a non-invasive, tissue-repair alternative, this cohort shows high adoption intention
• Per-session value: GTPS requires 16–24 sessions for a full protocol — among the highest session-count indications for PEMF. At ₱1,500–₱2,500 per session, complete treatment generates ₱24,000–₱60,000 per patient, making it a high-value clinic segment

Contraindications

PEMF is contraindicated for: active pacemaker or implanted cardiac device; pregnancy; active malignancy in the hip/gluteal region; active local infection or septic bursitis (requires aspiration and antibiotics first). Hip prosthesis patients: PEMF can be applied after confirming non-ferromagnetic implant material with the operating surgeon; modern ceramic/titanium prostheses are generally compatible.

Frequently Asked Questions

Is hip bursitis the same as greater trochanteric pain syndrome?

Not exactly. "Hip bursitis" was the historical term when bursal inflammation was believed to be the primary pathology. Current evidence shows most lateral hip pain involves gluteal tendinopathy (degenerative change in the gluteus medius or minimus tendon insertion) as the primary driver, with secondary bursal irritation. The distinction matters clinically: pure bursitis responds to anti-inflammatory treatment alone, while tendinopathy requires both anti-inflammatory and tendon-repair intervention. PEMF addresses both simultaneously, making it appropriate regardless of whether the traditional or updated classification is used.

How long does GTPS take to resolve with PEMF?

Acute GTPS (first episode, duration under 3 months): 8–12 sessions over 4–6 weeks, with significant pain reduction from Session 4–6. Chronic GTPS (over 3 months, or recurrent after injection): 16–24 sessions over 8–12 weeks. Chronic cases with established tendinopathy confirmed on imaging (high-signal change on MRI, hypoechoic zones on ultrasound) require the full protocol duration for structural remodeling, even if pain resolves early.

Can PEMF prevent the need for another corticosteroid injection?

This is the primary value proposition for many GTPS patients — especially those who have had 2–3 previous injections that provided only temporary relief. PEMF addresses the structural tendinopathy that injections do not; patients completing a full PEMF course (including the consolidation phase) show significantly lower recurrence rates than injection-only management in the clinical evidence base for analogous peritendinous conditions.

Can patients exercise while undergoing PEMF for hip bursitis?

Modified activity — not complete rest — is the recommended approach. Avoiding compressive hip positions (cross-leg sitting, high-step climbing, deep adduction) is important during the acute phase. Gluteal strengthening exercises can typically begin in Week 2 under PEMF-assisted protocols, compared to Week 3–4 in standard management. Patients are encouraged to maintain general fitness through pool-based exercise or cycling at low resistance during the acute phase.